View in EDS

Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial.

Saved in:
Bibliographic Details
Title: Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial.
Authors: Pagano G; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland. gennaro.pagano@roche.com.; University of Exeter Medical School, London, UK. gennaro.pagano@roche.com., Monnet A; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Reyes A; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Ribba B; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland., Svoboda H; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.; Roche Diagnostics GmbH, Penzberg, Germany., Kustermann T; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland., Simuni T; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Postuma RB; Department of Neurology, McGill University and Montreal Neurological Institute, Montreal, Quebec, Canada., Pavese N; Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne, UK., Stocchi F; University San Raffaele Roma and the Institute for Research and Medical Care, IRCCS San Raffaele Pisana, Rome, Italy., Brockmann K; Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases (DZNE), University of Tuebingen, Tuebingen, Germany., Smigorski K; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland., Gerbaldo V; Excelya Germany GmbH, Freiburg, Germany., Fontoura P; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Doody R; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech USA Inc., San Francisco, CA, USA., Kerchner GA; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland., Brundin P; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland., Marek K; Institute for Neurodegenerative Disorders, New Haven, CT, USA., Bonni A; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland., Nikolcheva T; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Corporate Authors: PASADENA Investigators, Prasinezumab Study Group
Source: Nature medicine [Nat Med] 2024 Dec; Vol. 30 (12), pp. 3669-3675. Date of Electronic Publication: 2024 Oct 08.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39379705
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Pagano+G%22">Pagano G</searchLink>; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland. gennaro.pagano@roche.com.; University of Exeter Medical School, London, UK. gennaro.pagano@roche.com.<br /><searchLink fieldCode="AU" term="%22Monnet+A%22">Monnet A</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Reyes+A%22">Reyes A</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Ribba+B%22">Ribba B</searchLink>; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Svoboda+H%22">Svoboda H</searchLink>; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.; Roche Diagnostics GmbH, Penzberg, Germany.<br /><searchLink fieldCode="AU" term="%22Kustermann+T%22">Kustermann T</searchLink>; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Simuni+T%22">Simuni T</searchLink>; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Postuma+RB%22">Postuma RB</searchLink>; Department of Neurology, McGill University and Montreal Neurological Institute, Montreal, Quebec, Canada.<br /><searchLink fieldCode="AU" term="%22Pavese+N%22">Pavese N</searchLink>; Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne, UK.<br /><searchLink fieldCode="AU" term="%22Stocchi+F%22">Stocchi F</searchLink>; University San Raffaele Roma and the Institute for Research and Medical Care, IRCCS San Raffaele Pisana, Rome, Italy.<br /><searchLink fieldCode="AU" term="%22Brockmann+K%22">Brockmann K</searchLink>; Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases (DZNE), University of Tuebingen, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Smigorski+K%22">Smigorski K</searchLink>; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Gerbaldo+V%22">Gerbaldo V</searchLink>; Excelya Germany GmbH, Freiburg, Germany.<br /><searchLink fieldCode="AU" term="%22Fontoura+P%22">Fontoura P</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Doody+R%22">Doody R</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech USA Inc., San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Kerchner+GA%22">Kerchner GA</searchLink>; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Brundin+P%22">Brundin P</searchLink>; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Marek+K%22">Marek K</searchLink>; Institute for Neurodegenerative Disorders, New Haven, CT, USA.<br /><searchLink fieldCode="AU" term="%22Bonni+A%22">Bonni A</searchLink>; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Nikolcheva+T%22">Nikolcheva T</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22PASADENA+Investigators%22">PASADENA Investigators</searchLink><br /><searchLink fieldCode="CA" term="%22Prasinezumab+Study+Group%22">Prasinezumab Study Group</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502015%22">Nature medicine</searchLink> [Nat Med] 2024 Dec; Vol. 30 (12), pp. 3669-3675. <i>Date of Electronic Publication: </i>2024 Oct 08.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Company%22">Nature Publishing Company </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502015 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1546-170X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210788956%22">10788956 </searchLink><i>NLM ISO Abbreviation: </i>Nat Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39379705
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41591-024-03270-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3669
    Titles:
      – TitleFull: Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Pagano G
      – PersonEntity:
          Name:
            NameFull: Monnet A
      – PersonEntity:
          Name:
            NameFull: Reyes A
      – PersonEntity:
          Name:
            NameFull: Ribba B
      – PersonEntity:
          Name:
            NameFull: Svoboda H
      – PersonEntity:
          Name:
            NameFull: Kustermann T
      – PersonEntity:
          Name:
            NameFull: Simuni T
      – PersonEntity:
          Name:
            NameFull: Postuma RB
      – PersonEntity:
          Name:
            NameFull: Pavese N
      – PersonEntity:
          Name:
            NameFull: Stocchi F
      – PersonEntity:
          Name:
            NameFull: Brockmann K
      – PersonEntity:
          Name:
            NameFull: Smigorski K
      – PersonEntity:
          Name:
            NameFull: Gerbaldo V
      – PersonEntity:
          Name:
            NameFull: Fontoura P
      – PersonEntity:
          Name:
            NameFull: Doody R
      – PersonEntity:
          Name:
            NameFull: Kerchner GA
      – PersonEntity:
          Name:
            NameFull: Brundin P
      – PersonEntity:
          Name:
            NameFull: Marek K
      – PersonEntity:
          Name:
            NameFull: Bonni A
      – PersonEntity:
          Name:
            NameFull: Nikolcheva T
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2024 Dec
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1546-170X
          Numbering:
            – Type: volume
              Value: 30
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Nature medicine
              Type: main
ResultId 1